GlassScriptPhysician profile
Dimitry M Palceski
NPI 1265407290
$23,249.75
in general payments reported to CMS, 2019-2025
48 companies · $3,205 in 2025
The $3,205 reported for 2025 was more than what 85% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,724 · 2020: $4,750 · 2021: $2,264 · 2022: $2,387 · 2023: $2,697 · 2024: $3,223 · 2025: $3,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,931 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,930.65 |
| Education | $194.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $4,043.55 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Abbvie INC. | $3,700.68 | 2019-2025 | |
| Biofrontera INC. | $2,999.11 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $1,496.00 | 2019-2025 | Klisyri |
| Genzyme Corporation | $1,088.04 | 2019-2025 | |
| Ucb, INC. | $957.16 | 2019-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $848.65 | 2019-2025 | |
| Leo Pharma INC. | $723.93 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $693.21 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $683.55 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $601.73 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $528.53 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $505.40 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $486.87 | 2022-2024 | Vtama |
| Incyte Corporation | $409.52 | 2021-2025 | Opzelura |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimitry Palceski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.